BR005-036C / Brise Pharma - LARVOL DELTA

Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults (clinicaltrials.gov) - P3 | N=1000 | Not yet recruiting | Sponsor: Brise Pharmaceuticals Co., Ltd.

New P3 trial • CNS Disorders • Migraine

Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults (clinicaltrials.gov) - P2/3 | N=2079 | Not yet recruiting | Sponsor: Brise Pharmaceuticals Co., Ltd.

New P2/3 trial • CNS Disorders • Migraine

Evidence-based medicine advances in de-escalation strategies for local surgical treatment of breast cancer (PubMed, Zhonghua Yi Xue Za Zhi) - "This article systematically reviews five pathways for de-escalation of local surgical treatment in breast cancer and their key clinical evidence: selective exemption from breast surgery after neoadjuvant therapy by verifying pathologic complete response through imaging combined with vacuum-assisted biopsy (NRG-BR005, MICRA, MD Anderson Exceptional Responders trials, etc.); active surveillance replacing immediate surgery for low-risk ductal carcinoma in situ (COMET, LORIS, LORD, etc.); percutaneous ablation replacing partial breast-conserving surgery (ICE3, PO-RAFAELO, etc.); exemption from sentinel lymph node biopsy for patients with clinically negative lymph nodes and negative axillary ultrasound (INSEMA, SOUND, etc.); and reducing the false-negative rate (FNR) by using sentinel combined with targeted axillary dissection to avoid axillary lymph node dissection in initially node-positive patients who convert to clinically node-negative after neoadjuvant therapy (ACOSOG..."

Journal • Review • Breast Cancer • Oncology • Solid Tumor